Benefits of Trimetazidine in MAFLD Pateints

• Status: Recruiting
• Trial end date: 2025-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Objective of this study is to determine the clinical benefits of trimetazidine in improvement of MAFLD

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: October 6 University
• Treatments: Furosemide; Hypoglycemic Agents; Niacin; Nicotinic Acids; Trimetazidine

Criteria

Inclusion Criteria:Patients presented to hepatology clinic .

• Patients are diagnosed by ultrasonography and laboratory tests for liver and lipids.

• Patients with comorbidites like hypertension,diabetes,dyslipidemia, insuline resistance , increase in west circumstanses

Exclusion Criteria:Exclusion criteria included the presence of liver disease due to any of the following:

• viral hepatitis (HBV, HCV)

• acute systemic disease

• cystic fibrosis, coeliac disease

• alcoholism pateints

• autoimmune hepatitis, drug toxicity and drugs known to induce steatosis (e.g. valproate, amiodarone orprednisone)

• the use of nonsteroidal anti-inflammatory drugs,antibiotics,sglt2,dpp4,statins,glp1

• Patient with age below 18 or above 60